FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

In continuation of my update on Sutent

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

In continuation of my update on "antisense drugs"....
Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

Merck receives FDA approval for Victrelis to treat chronic hepatitis C

In continuation of my update on Victrelis (Boceprevir)

Merck receives FDA approval for Victrelis to treat chronic hepatitis C

New insect repellant may be thousands of times stronger than DEET

In continuation of mosquito repellants and DEET

Researchers report the identification and characterization of an Orco family agonist, VUAA1, using the Anopheles gambiae coreceptor (AgOrco) and other orthologues. These studies reveal that the Orco family can form functional ion channels in the absence of an odor-binding OR, and in addition, demonstrate a first-in-class agonist to further research in insect OR signaling. In light of the extraordinary conservation and widespread expression of the Orco family, VUAA1 represents a powerful new family of compounds that can be used to disrupt the destructive behaviors of nuisance insects, agricultural pests, and disease vectors alike...

New insect repellant may be thousands of times stronger than DEET

Ref : http://www.pnas.org/content/early/2011/05/04/1102425108#aff-1

Novel two-drug combination cures young patient with extensively drug-resistant tuberculosis

The combination of meropenem (above structure)  with clavulanate (right structure-potassium salt)  has high antimycobacterial activity in vitro against extensively drug-resistant Mycobacterium tuberculosis strains. Researchers report the successful use of this combination in association with linezolid (below structure)  in the management of an advanced extensively drug-resistant tuberculosis disease with complex second-line drug resistance in a 14-year-old teenager.

Ref : 1.Meropenem/Clavulanate and Linezolid Treatment for Extensively Drug-Resistant Tuberculosis

    2. http://www.einstein.yu.edu/uploadedFiles/PHD/2010%20Faculty%20Research%20Book.pdf

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

We know the recent development about 'FAMPYRA' by "European Medicines Agency".....

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS...

First EffRx NDA accepted for filing by the FDA...

EffRx Pharmaceuticals SA, an Epalinges/Lausanne, Switzerland based drug delivery company announces that the New Drug Application (NDA) for the company's lead development program EX101 has been accepted for filing by the US Food and Drug Administration. EX101 is a proprietary buffered effervescent dosage form of alendronate sodium administered once weekly for treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. The EX101 formulation is the first and only effervescent bisphosphonate alternative to tablets. EX101 has a pleasant taste of strawberry and is quickly and completely dissolved. 

About Alendronate : Alendronic acid or alendronate sodium ( sold as Fosamax by Merck) is a bisphosphonate drug used for osteoporosis and several other bone diseases. It is marketed alone as well as in combination with vitamin D (2,800 U and 5600 U, under the name Fosamax+D). Merck's U.S. patent on alendronate expired in 2008 and Merck lost a series of appeals to block a generic version of the drug from being certified by the FDA. On February 6, 2008, the US FDA approved the first generic versions of alendronate, which were marketed by Barr Pharmaceuticals and Teva Pharmaceuticals USA. Teva Pharmaceuticals manufactures generic alendronate in 5-milligram, 10-milligram, and 40-milligram daily doses, and in 35-milligram and 70-milligram weekly doses, while Barr made generic alendronate in 70-milligram tablets, which were taken once weekly. Barr pharmaceuticals were subsequently acquired by Teva in July 2008...

Ref : http://www.effrx.com/firsteffrxnda.htm

Regenerating nerve cells: Research offers hope in new treatment for spinal cord injuries

Regenerating nerve cells: Research offers hope in new treatment for spinal cord injuries

Clinical study: Celecoxib drug may treat breast cancer

In continuation of m update on Celecoxib

Clinical study: Celecoxib drug may treat breast cancer

World's first urine-based tuberculosis diagnostics tool

World's first urine-based tuberculosis diagnostics tool